-

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223417

Enrollment

666

Registered

2016-12-22

Start date

2013-09-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

investigational material(s) Generic name etc : - INN of investigational material : avelumab Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational materia

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -

Exclusion criteria

Exclusion criteria: -

Design outcomes

Primary

Measure	Time frame
safety -	—

Secondary

Measure	Time frame
efficacy exploratory pharmacokinetics -	—

Countries

Japan

Outcome results